ZAPI GROUP Showcases New Solutions in Material Automation at LogiMAT 2024
19.3.2024 16:00:00 EET | Business Wire | Press release
ZAPI GROUP, a global leader in electrification, announced today it is showcasing its solutions for the material handling and electrification industries at LogiMAT 2024. At the event, ZAPI GROUP is announcing the expansion of BlueBotics, a ZAPI GROUP company and leader in autonomous navigation technology. BlueBotics has partnered with Pramac, a leading global supplier of warehouse material handling equipment, and expanded its ANT server mission and fleet management software. These milestones bolster ZAPI GROUP's standing as a comprehensive autonomous navigation and AGV fleet management provider for electrification.
"The expansion of BlueBotics is an exciting milestone as ZAPI GROUP continues to grow its capabilities to serve the global AGV and material handling sectors," noted Lloyd Gomm, Global Marketing Director at ZAPI GROUP. "BlueBotics’ consistent innovation in navigation software enables the company to broaden the spectrum of solutions and integrated systems available to our OEM customers. LogiMAT presents an opportunity to showcase these developments and other product innovations with the industry.”
The ZAPI GROUP is exhibiting at LogiMAT 2024 in Stuttgart from March 19 - 21 in hall 6, booth 6C61. They provide a wide array of capabilities for OEMs with a range of electrification and automation solutions for material handling machines and robots, including inverters and controllers, electric motors, high-frequency battery chargers and accessories. Its companies leading innovation across AGV and material handling sectors include BlueBotics, Zapi, Inmotion Technologies, Delta-Q Technologies, Zivan, Schabmüller, 4E Consulting, Best Motor and ZTP.
At the ZAPI GROUP booth at LogiMAT, the BlueBotics team is announcing the agility of its ANT server fleet management software to control not only more than 100 “ANT driven” customer vehicles but also now VDA 5050-compliant AGVs and AMRs. The company will also demo Pramac’s X-ACT HYBRIX robot, a new line of X-ACT mobile logistics robots powered by BlueBotics’ latest version of its software, as part of its on-stand multi-brand AGV/AMR fleet demo.
“We are thrilled to further expand our suite of autonomous navigation and AGV fleet management solutions,” said BlueBotics’ CEO, Dr. Nicola Tomatis. “BlueBotics has a proven track record of developing autonomous solutions for a variety of mobile robotic platforms. These solutions continue to complement ZAPI GROUP's existing system integration capabilities, advance its electrification mission and enhance OEMs’ access to robust solutions for material handling automation.”
The ZAPI GROUP recently hosted industry leaders at its annual virtual conference, The Future of Electrification. This was the company’s third year hosting the event aimed to drive education and innovations for electrification across its key industries.
To learn more about ZAPI GROUP and its companies, visit them at LogiMAT 2024 (hall 6, stand 6C61).
About ZAPI GROUP
ZAPI GROUP is engineering the transition to an all-electric future with a highly integrated product portfolio, including motion controllers, electric motors, high-frequency battery chargers, and autonomous navigation software for application in full-electric and hybrid vehicles. As a global electrification leader with deep systems experience, leading innovations, and an obsession with driving customers' success, ZAPI GROUP now counts more than 1700 employees worldwide with total annual revenue of more than 700 million US dollars.
For more information about the group, visit www.zapigroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319748003/en/
Contact information
AnnMarie Carson, Communiqué PR
Phone: (206) 282-4923 ext. 119
Email: zapigrouppr@communiquepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom